Advertisement

MicroRNAs: Biomarkers, Diagnostics, and Therapeutics

  • Weili HuangEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1617)

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs (21–23 nucleotides in length) that regulate gene expression at translational or posttranslational levels. The major regulatory mechanisms include translational repression or mRNA degradation (Filipowicz et al., Curr Opin Struct Biol 15:331–341, 2005).

Aberrant expression of miRNAs has been found to be associated with a variety of human diseases such as cancers/tumors, diabetes, viral infections, cardiovascular diseases, neurodegenerative diseases, and other diseases (Wang et al., J Cell Physiol 23:25–30, 2016; Lawrie, MicroRNAs in medicine, 2013). The expression of miRNAs is tissue specific and can be used to identify tumor type and its origin (Mishra and Merlino, J Clin Invest 119:2119–2123, 2009). Many investigations suggest that the miRNA-expression profiles are novel diagnostic and prognostic biomarkers for multiple human diseases. Manipulating relevant miRNA expression or function may serve as potential therapeutic strategies for different diseases.

Key words

Biomarkers Diagnostics miRNA Prognostics Regulation Therapeutics 

References

  1. 1.
    Giraldez AJ, Mishima Y, Rihel J, Grocock RJ, Van Dongen S, Inoue K, Enright AJ, Schier AF (2006) Zebrafish miR-430 promotes deadenylation and clearance of maternal mRNAs. Science 312:75–79. doi: 10.1126/science.1122689 CrossRefPubMedGoogle Scholar
  2. 2.
    Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS (2005) Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 15:331–341. doi: 10.1016/j.sbi.2005.05.006 CrossRefPubMedGoogle Scholar
  3. 3.
    Wang J, Chen J, Sen S (2016) MicroRNA as biomarkers and diagnostics. J Cell Physiol 23:25–30. doi: 10.1002/jcp.25056 CrossRefGoogle Scholar
  4. 4.
    Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM (2003) bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113:25–36. doi: 10.1016/S0092-8674(03)00231-9 CrossRefPubMedGoogle Scholar
  5. 5.
    Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297. doi: 10.1016/S0092-8674(04)00045-5 CrossRefPubMedGoogle Scholar
  6. 6.
    Chen CZ, Li L, Lodish HF, Bartel DP (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303:83–86. doi: 10.1126/science.1091903 CrossRefPubMedGoogle Scholar
  7. 7.
    Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518. doi: 10.1073/pnas.0804549105 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lawrie CH (2013) MicroRNAs in medicine. John Wiley & Sons, Inc., Hoboken, NJ. doi: 10.1002/9781118300312 CrossRefGoogle Scholar
  9. 9.
    Challagundla KB, Fanini F, Vannini I, Wise P, Murtadha M, Malinconico L, Cimmino A, Fabbri M (2014) microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics. Expert Rev Mol Diagn 14:565–574. doi: 10.1586/14737159.2014.922879 CrossRefPubMedGoogle Scholar
  10. 10.
    Palmero EI, de Campos SG, Campos M, de Souza NC, Guerreiro ID, Carvalho AL, Marques MM (2011) Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol 34:363–370. doi: 10.1590/S1415-47572011000300001 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mishra PJ, Merlino G (2009) MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 119:2119–2123. doi: 10.1172/JCI40107 PubMedPubMedCentralGoogle Scholar
  12. 12.
    Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM (2006) MicroRNA expression and function in cancer. Trends Mol Med 12:580–587. doi: 10.1016/j.molmed.2006.10.006 CrossRefPubMedGoogle Scholar
  13. 13.
    Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:15524–15529. doi: 10.1073/pnas.242606799 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070. doi: 10.1158/0008-5472.CAN-05-1783 CrossRefPubMedGoogle Scholar
  15. 15.
    Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, Dell’Aquila ML, Alder H, Rassenti L, Kipps TJ, Bullrich F, Negrini M, Croce CM (2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 101:11755–11760. doi: 10.1073/pnas.0404432101 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM (2005) A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 352:1667–1676. doi: 10.1056/NEJMMoa050995 CrossRefPubMedGoogle Scholar
  17. 17.
    Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189–198. doi: 10.1016/j.ccr2006.01.025 CrossRefPubMedGoogle Scholar
  18. 18.
    Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25:2537–2545. doi: 10.1038/sj.onc.1209283 CrossRefPubMedGoogle Scholar
  19. 19.
    Qi J, Wang J, Katayama H, Sen S, Liu SM (2013) Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 60:135–142. doi: 10.4149/neo_2013_018 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Menard S, Croce CM (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67:8699–8707. doi: 10.1158/0008-5472.CAN-07-1936 CrossRefPubMedGoogle Scholar
  21. 21.
    Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, Croce CM (2006) MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathological features and clinical behavior. J Clin Oncol 24:4677–4684. doi: 10.1200/JCO.2005.05.5194 CrossRefPubMedGoogle Scholar
  22. 22.
    Wang J, Sen S (2011) MicroRNA functional network in pancreatic cancer: from biology to biomarkers of disease. J Biosci 36:481–491. doi: 10.1007/s12038-011-9083-4 CrossRefPubMedGoogle Scholar
  23. 23.
    He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A (2005) The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 102:19075–19080. doi: 10.1073/pnas.0509603102 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M, Croce CM, Fusco A (2006) MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 13:497–508. doi: 10.1677/erc.1.01209 CrossRefPubMedGoogle Scholar
  25. 25.
    Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334:1351–1358. doi: 10.1016/j.bbrc.2005.07.030 CrossRefPubMedGoogle Scholar
  26. 26.
    Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Visakorpi T (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67:6130–6135. doi: 10.1158/0008-5472.CAN-07-0533 CrossRefPubMedGoogle Scholar
  27. 27.
    Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nat Cell Biol 435:834–838. doi: 10.1038/nature03702 Google Scholar
  28. 28.
    Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z, Cohen D, Chajut A, Barshack I (2008) MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:462–469. doi: 10.1038/nbt1392 CrossRefPubMedGoogle Scholar
  29. 29.
    Wandt H, Haferlach T, Thiede C, Ehninger G (2010) WHO classification of myeloid neoplasms and leukemia. Blood 115:748–749. doi: 10.1182/blood-2009-10-249664 CrossRefPubMedGoogle Scholar
  30. 30.
    Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39:673–677. doi: 10.1038/ng2003 CrossRefPubMedGoogle Scholar
  31. 31.
    Esteller M (2011) Noncoding RNAs in human disease. Nat Rev Genet 12:861–874. doi: 10.1038/nrg3074 CrossRefPubMedGoogle Scholar
  32. 32.
    Huang JT, Wang J, Srivastava V, Sen S, Liu SM (2014) MicroRNA machinery genes as novel biomarkers for cancer. Front Oncol 4:113. doi: 10.3389/fonc.2014.00113 PubMedPubMedCentralGoogle Scholar
  33. 33.
    Shenouda SK, Alahari SK (2009) MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28:369–378. doi: 10.1007/s10555-009-9188-5 CrossRefPubMedGoogle Scholar
  34. 34.
    Lawrie CH, Soneji S, Marafioti T, Cooper CDO, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, Wainscoat JS, Hatton CSR (2007) MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 121:1156–1161. doi: 10.1002/ijc.22800 CrossRefPubMedGoogle Scholar
  35. 35.
    Etheridge A, Lee I, Hood L, Galas D, Wang K (2011) Extracellular microRNA: a new source of biomarkers. Mutat Res 717:85–90. doi: 10.1016/j.mrfmmm.2011.03.004 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28:655–661. doi: 10.1016/j.urolonc.2009.01.027 CrossRefPubMedGoogle Scholar
  37. 37.
    Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT (2009) Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15:5473–5477. doi: 10.1158/1078-0432.CCR-09-0736 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Nielsen LB, Wang C, Sorensen K, Bang-Berthelsen CH, Hansen L, Andersen ML, Hougaard P, Juul A, Zhang CY, Pociot F, Mortensen HB (2012) Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012:896362. doi: 10.1155/2012/896362 PubMedPubMedCentralGoogle Scholar
  39. 39.
    Liu Y, Gao G, Yang C, Zhou K, Shen B, Liang H, Jiang X (2014) The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int J Mol Sci 15:10567–10577. doi: 10.3390/ijms150610567 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Yang Z, Chen H, Si H, Li X, Ding X, Sheng Q, Chen P, Zhang H (2014) Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol 51:823–831. doi: 10.1007/s00592-014-0617-8 CrossRefPubMedGoogle Scholar
  41. 41.
    Zhao C, Dong J, Jiang T, Shi Z, Yu B, Zhu Y, Chen D, Xu J, Huo R, Dai J, Xia Y, Pan S, Hu Z, Sha J (2011) Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One 6:e23925. doi: 10.1371/journal.pone.0023925 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Skalsky RL, Cullen BR (2010) Viruses, microRNAs, and host interactions. Annu Rev Microbiol 64:123–141. doi: 10.1146/annurev.micro.112408.134243 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H (2010) Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antivir Res 88:169–175. doi: 10.1016/j.antiviral.2010.08.008 CrossRefPubMedGoogle Scholar
  44. 44.
    Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K (2009) Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 50:453–460. doi: 10.1016/j.jhep.2008.06.010 CrossRefPubMedGoogle Scholar
  45. 45.
    Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, Saib A, Voinnet O (2005) A cellular microRNA mediates antiviral defense in human cells. Science 308:557–560. doi: 10.1126/science.1108784 CrossRefPubMedGoogle Scholar
  46. 46.
    Chen AK, Sengupta P, Waki K, Van Engelenburg SB, Ochiya T, Ablan SD, Freed EO, Lippincott-Schwartz J (2014) MicroRNA binding to the HIV-1 Gag protein inhibits Gag assembly and virus production. Proc Natl Acad Sci U S A 111:E2676–E2683. doi: 10.1073/pnas.1408037111 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Anadol E, Schierwagen R, Elfimova N, Tack K, Schwarze-Zander C, Eischeid H, Noetel A, Boesecke C, Jansen C, Dold L, Wasmuth JC, Strassburg CP, Spengler U, Rockstroh JK, Odenthal M, Trebicka J (2015) Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients. Hepatology 61:46–55. doi: 10.1002/hep.27369 CrossRefPubMedGoogle Scholar
  48. 48.
    Romaine SP, Tomaszewski M, Condorelli G, Samani NJ (2015) MicroRNAs in cardiovascular disease: an introduction for clinicians. Heart 101:921–928. doi: 10.1136/heartjnl-2013-305402 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Ai J, Zhang R, Li Y, Pu JL, Lu YJ, Jiao JD, Li K, Yu B, Li ZQ, Wang RR, Wang LH, Li Q, Wang N, Shan HL, Li ZY, Yang BF (2010) Circulating microRNA as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 391:73–77. doi: 10.1016/j.bbrc.2009.11.005 CrossRefPubMedGoogle Scholar
  50. 50.
    Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk PJ, Kiechl S, Mayr M (2012) Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 60:290–299. doi: 10.1016/j.jacc.2012.03.056 CrossRefPubMedGoogle Scholar
  51. 51.
    Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659–666. doi: 10.1093/eurheartj/ehq013 CrossRefPubMedGoogle Scholar
  52. 52.
    Devaux Y, Vausort M, McCann GP, Kelly D, Collignon O, Ng LL, Wagner DR, Squire IB (2013) A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS One 8:e70644. doi: 10.1371/journal.pone.0070644 CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Fineberg SK, Kosik KS, Davidson BL (2009) MicroRNAs potentiate neural development. Neuron 64:303–309. doi: 10.1016/j.neuron.2009.10.020 CrossRefPubMedGoogle Scholar
  54. 54.
    Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, Bassel-Duby R, Sanes JR, Olson EN (2009) MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326:1549–1554. doi: 10.1126/science.1181046 CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang GL, Huang QW, Rigoutsos I, Nelson PT (2008) The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme. J Neurosci 28:1213–1223. doi: 10.1523/JNEUROSCI.5065-07.2008 CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Wang G, van der Walt JM, Mayhew G, Li YJ, Züchner S, Scott WK, Martin ER, Vance JM (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82:283–289. doi: 10.1016/j.ajhg.2007.09.021 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Margis R, Margis R, Rieder CR (2011) Identification of blood microRNAs associated to Parkinsonis disease. J Biotechnol 152:96–101. doi: 10.1016/j.jbiotec.2011.01.023 CrossRefPubMedGoogle Scholar
  58. 58.
    Zhao Z, Zhao Q, Warrick J, Lockwood CM, Woodworth A, Moley KH, Gronowski AM (2012) Circulating microRNA miR-323-3p as a biomarker of ectopic pregnancy. Clin Chem 58:896–905. doi: 10.1373/clinchem.2011.179283 CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D (2008) Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 58:1001–1009. doi: 10.1002/art.23386 CrossRefPubMedGoogle Scholar
  60. 60.
    Paraskevi A, Theodoropoulos G, Papaconstantinou I, Mantzaris G, Nikiteas N, Gazouli M (2012) Circulating MicroRNA in inflammatory bowel disease. J Crohns Colitis 6:900–904. doi: 10.1016/j.crohns.2012.02.006 CrossRefPubMedGoogle Scholar
  61. 61.
    Zhang Y, Jia Y, Zheng RY, Guo YJ, Wang Y, Guo H, Fei MY, Sun SH (2010b) Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56:1830–1838. doi: 10.1373/clinichem.2010.147850 CrossRefPubMedGoogle Scholar
  62. 62.
    Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6:e23937. doi: 10.1371/journal.pone.0023937 CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Ben-Dov IZ, Tan YC, Morozov P, Wilson PD, Rennert H, Blumenfeld JD, Tuschl T (2014) Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline. PLoS One 9:e86856. doi: 10.1371/journal.pone.0086856 CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kümpers P, Faulhaber-Walter R, Haller H, Fliser D, Thum T (2011) Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol 6:1540–1546. doi: 10.2215/CJN.00430111 CrossRefPubMedGoogle Scholar
  65. 65.
    Aigner A (2008) Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des 14:3603–3619. doi: 10.2174/138161208786898815 CrossRefPubMedGoogle Scholar
  66. 66.
    Yang N (2015) An overview of viral and nonviral delivery systems for microRNA. Int J Pharm Investig 5:179–181. doi: 10.4103/2230-973X.167646 CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
  68. 68.
    Chugh P, Dittmer DP (2012) Potential pitfalls in microRNA profiling. Wiley Interdiscip Rev RNA 3:601–616. doi: 10.1002/wrna.1120 CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Wang Y, Zheng D, Tan Q, Wang MX, Gu LQ (2011) Nanopore-based detection of circulating microRNAs in lung cancer patients. Nat Nanotechnol 6:668–674. doi: 10.1038/nnano.2011.147 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Miracle Query, IncorporatedEugeneUSA

Personalised recommendations